safety and efficacy of pegylated interferon alfa-2a for the treatment of hepatitis c in patients with major thalassemia

background: hepatitis c virus (hcv) infection is the most common transfusion transmitted disease in poly-transfused patients worldwide. in this study we aimed to evaluate the effects of pegylated interferon alfa-2a (peg-ifn a-2a) in reducing serum alt and eradicating serum hepatitis c virus (hcv) rna in hcv infected polytransfused thalassemic patients. materials and methods: a cohort of 51 hcv-rna positive thalassemic patients were enrolled to our study and received 180 µg peg-ifn a-2a once-weekly for 48 weeks. the primary end point was sustained virological response (svr). the secondary outcome was normalization of alt. patient safety was assured by monthly, and if needed, weekly laboratory assessment and visits. results: of 52 patients, 42 participants completed the treatment schedule. a sustained virological response (svr) was attained in 22/51 (43%) cases. among non-responders or relapsers to previous hcv antiviral therapy, 9/27 (33%) attained an svr. five patients died during treatment and 3 subjects discontinued the therapy because of adverse effects. adverse events were generally mild, and laboratory abnormalities were rare. conclusion: a course of 48-week peg-ifn a-2a monotherapy is effective in eradicating hcv-rna during treatment. but about one third of thalassemic patients would relapse within 6 months of treatment schedule completion, in whom combination therapy is needed.